Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Max Bayer

Pharma Reporter

Infectious disease professionals, bracing for an overhaul of the CDC’s vaccine advisory group, are in discussions to stand up a parallel committee of experts outside …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Max Bayer

Pharma Reporter

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Max Bayer

Pharma Reporter

Sign up to read this article for free.

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence